Key Drivers
- Strong liquidity
- Weak coverage
- Negative earnings
AIAI Summary
SGRY should be viewed less as a revenue-growth story and more as a leveraged operating-earnings turnaround: the stock can rerate only if management converts continued same-facility growth and reaffirmed guidance into consistent EBIT, free cash flow, and improved interest coverage, because high debt and weak earnings quality remain the main overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Weak coverage
- •Negative earnings
SGRY has solid liquidity and full-year cash generation, but high leverage and weak interest coverage are压? No; keep concise and clear: SGRY has solid liquidity and full-year cash generation, but high leverage and weak interest coverage are eroding profits and keeping shareholder earnings negative despite a modestly cheap valuation.
Price Behavior
Key Price Behavior Insights:
- •Range consolidation
- •Support holding
- •Capped upside
Over the last month, SGRY has been choppy and range-bound near $14, with buyers defending $13.80-$14.00 but $14.70-$14.75 still capping upside.
Rally to $14.73 faded back to support in late
Sentiment & News
Key News Insights:
- •Smaller loss
- •Revenue growth
- •Guidance steady
Surgery Partners posted a smaller-than-expected Q1 loss, grew revenue year over year, and left full-year 2026 guidance unchanged despite ongoing headwinds.
The results are mildly positive for SGRY, showing operational resilience and a stable outlook even as challenges remain
Similar Companies in Healthcare
Other companies in the same sector with AI ratings